Vitality Watch

Dossier clinicaltrials review 24-jun-2026
Narrative review or expert overview without new data

Evaluation of Frailty in Patients With Fibrosing Interstitial Lung Diseases: Prognostic and Therapeutic Impact

Key claim: Comprehensive frailty and sarcopenia assessment may identify older fibrosing ILD patients at higher risk of poor prognosis and antifibrotic treatment intolerance, but their combined prognostic impact remains unexplored.

Abstract

Fibrosing interstitial lung diseases (ILDs), with idiopathic pulmonary fibrosis being the most common form, primarily affect older individuals and have a poor prognosis, with a median survival of 3 to 5 years. While antifibrotic treatments such as nintedanib and pirfenidone can slow disease progression, their efficacy is often limited by side effects, particularly in elderly patients. A comprehensive patient assessment, including evaluations of frailty and sarcopenia, could optimize care by identifying those at risk for poor outcomes or poor treatment tolerance. Frailty, characterized by reduced physiological reserves, and sarcopenia, defined as a loss of muscle mass and strength, are both associated with increased mortality and morbidity risks. Although their individual impacts on fibrosing ILDs have been documented, the combined effect of these two syndromes on patient prognosis remains unexplored, highlighting the need for further studies to guide therapeutic decision-making.

Why this matters

Comprehensive frailty and sarcopenia assessment may identify older fibrosing ILD patients at higher risk of poor prognosis and antifibrotic treatment intolerance, but their combined prognostic impact remains unexplored.

Source

Link

Briefing card

Evaluation of Frailty in Patients With Fibrosing Interstitial Lung Diseases: Prognostic and Therapeutic Impact
Stage: review · clinicaltrials · 24-jun-2026

Comprehensive frailty and sarcopenia assessment may identify older fibrosing ILD patients at higher risk of poor prognosis and antifibrotic treatment intolerance, but their combined prognostic impact remains unexplored.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: nct:NCT07004595

build build 880 · 2bcef25 · 2026-11-18